Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 26, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 200,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,523.5 pence per share; lowest price paid was 1,506 pence per share.
- Treasury Holdings (Settled): 497,821,327 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 498,281,327 shares (10.15% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,909,467,448 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 200,000 shares. Consequently, the percentage of shares held in Treasury increased to 10.15% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,909,467,448) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.15% including unsettled shares).
- Note that the repurchase price range (1,506 to 1,523.5 pence) reflects market conditions on March 26, 2013.